Cholecystokinin peptides, dopamine and schizophrenia — A review
- 1 January 1985
- journal article
- review article
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 9 (5-6) , 515-524
- https://doi.org/10.1016/0278-5846(85)90011-9
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patientsLife Sciences, 1985
- Neuronal Cholecystokinin: One or Multiple Transmitters?Journal of Neurochemistry, 1985
- Reduced cholecystokinin immunoreactivity in the cerebrospinal fluid of patients with psychiatric disordersLife Sciences, 1984
- The cholecystokinin analogue, caerulein, does not modulate dopamine release or dopamine-induced locomotor activity in the nucleus accumbens of ratNeuroscience Letters, 1984
- Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophreniaLife Sciences, 1983
- Increase in brain 125I-cholecystokinin (CCK) receptor binding following chronic haloperidol treatment, intracisternal 6-hydroxydopamine or ventral tegmental lesionsLife Sciences, 1983
- Modulation of [3H]-dopamine binding by cholecystokinin octapeptide (CCK-8)Peptides, 1982
- The influence of vasoactive intestinal polypeptide and cholecystokinin of prolactin release in rat and human monolayer culturesLife Sciences, 1981
- Influence of cholecystokinin octapeptide sulfate ester on brain monoamine metabolism in ratsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1981
- Effect of ceruletide on pituitary-hypothalamic peptides and on emotion in manPeptides, 1981